Grail said to be planning IPO in Hong Kong to raise $500M

Cancer cells image
Cancer detection maker Grail is said to be planning an IPO in Hong Kong to raise $500 million. (Pixabay)

Grail, which seeks to develop liquid biopsies to catch cancer early, is looking at an initial public offering in Hong Kong, Bloomberg reported.

If the IPO comes to fruition, the offering would help bolster the Asian market’s attempts to attract more biotech listings.

Although a final offering amount hasn’t been set, unnamed sources told Bloomberg that Grail may be seeking to raise as much as $500 million. Grail, like Shanghai Henlius Biotech, may be looking to take advantage of the Hong Kong exchange’s proposed new listing rules designed to entice early-stage biotech firms to the market, the news service said.

Featured Webinar

How to Streamline Your Clinical Research Organization's Processes End to End

Learn how implementing one platform leads to data consistency and ultimately facilitate faster clinical trials while reducing overall trial costs, leave behind spreadsheets and home-grown tools for a predictable trial and the ability to forecast unit delivery resulting in the optics you need to ensure a successful trial, and hear experts share industry trends of what is affecting the Clinical Research Organization industry today.

Grail declined to comment on the report, Bloomberg said.

Late last year, the Menlo Park, California-based company, which is backed by Bill Gates and Jeff Bezos, announced its screening test for a type of cancer commonly found in Asia would be launched in Hong Kong later this year. Other investors in Grail include Tencent Holdings, Bristol-Myers Squibb, Celgene, Johnson & Johnson Innovation and Merck.

Grail spun out of Illumina a little over a year ago, and the company raised $900 million in series B financing by last March. The money, along with $100 million in series A funding previously raised, was directed to support large-scale clinical trials involving hundreds of thousands of patients.

The company is focusing on tracking DNA shed by tumors that circulates in the blood.


Suggested Articles

Stanford University and its school of medicine have launched plans to survey the population of greater San Francisco for COVID-19.

Thermo Fisher's third-quarter revenue topped $8.52 billion, a 36% increase over the $6.27 billion raised during the same period in 2019.

The drug that treats atrial fibrillation, flecainide, has been around since the '80s. Grace Colón, CEO of InCarda, thinks it needs a face-lift.